Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kybella vs Asclera for NF1 Cutaneous Neurofibromas
NCT06120036Phase 1Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Dec 2022
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of Neobella and 10XB101 in neurofibromatosis type 1 (NF1) and cutaneous neurofibroma (cNF), sponsored by Massachusetts General Hospital. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 3 months. Started Dec 2022; status: completed.
02
Drugs
Neobella10XB101
03
Conditions
neurofibromatosis type 1 (NF1)cutaneous neurofibroma (cNF)
Beyond the preview
Go deeper on NCT06120036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06120036.